AbbVie Inc (ABBV)vsAuna S.A. (AUNA)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
AUNA
Auna S.A.
$4.41
-2.00%
HEALTHCARE · Cap: $333.25M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1289% more annual revenue ($62.82B vs $4.52B). ABBV leads profitability with a 5.8% profit margin vs 1.5%. AUNA trades at a lower P/E of 16.7x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AUNA
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for AUNA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Attractively priced relative to earnings
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 3.9% — below average capital efficiency
1.5% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : AUNA
The strongest argument for AUNA centers on Price/Book, P/E Ratio. Revenue growth of 13.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : AUNA
The primary concerns for AUNA are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 2.19 is elevated, increasing financial risk. Thin 1.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
AUNA carries more volatility with a beta of 1.03 — expect wider price swings.
AUNA is growing revenue faster at 13.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 49/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Auna S.A.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Auna S.A. is a leading telecommunications and digital services provider in Latin America, offering a diverse range of integrated solutions that enhance connectivity for both residential and business clients. The company's extensive portfolio includes high-speed internet, television, and mobile services, underscoring its commitment to innovation and superior customer experience. Auna's robust infrastructure and strategic positioning enable it to capitalize on the increasing demand for advanced telecommunications solutions, making it an attractive investment opportunity for institutional investors seeking exposure to the region's expanding digital economy.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?